Avanos Medical, Inc. ( (AVNS) ) has released its Q2 earnings. Here is a breakdown of the information Avanos Medical, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avanos Medical, Inc. is a medical technology company based in Alpharetta, Georgia, focusing on providing solutions for specialty nutrition and pain management, with a commitment to reducing opioid use and supporting patient recovery.
In its second quarter of 2025, Avanos Medical reported a modest increase in net sales by 1.9% to $175 million, driven by strong demand in its Specialty Nutrition Systems segment and growth in radiofrequency ablation products. However, the company faced a significant net loss of $76.8 million, primarily due to a $77 million goodwill impairment charge.
Key financial metrics showed a decline, with adjusted net income dropping to $7.9 million from $15.8 million the previous year, and adjusted EBITDA decreasing to $17 million from $26.8 million. Despite these challenges, the Specialty Nutrition Systems segment saw a 5.1% increase in net sales, while the Pain Management & Recovery segment experienced a 2.9% rise, bolstered by a 13.7% growth in radiofrequency ablation product sales.
Looking ahead, Avanos Medical maintains its 2025 revenue guidance between $665 million and $685 million, with adjusted diluted earnings per share expected to range from $0.75 to $0.95. The company remains focused on strategic transformations and mitigating tariff impacts to achieve its financial goals.